{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:33:49Z","timestamp":1790627629104,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003483","name":"Hebrew University of Jerusalem","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pulmonary embolism (PE) is a life-threatening condition often treated with unfractionated heparin (UFH) in intermediate high-risk patients. Activated Partial Thromboplastin Time (aPTT) is used to monitor UFH efficacy. We sought to evaluate the correlation between time in therapeutic range (TTR) and prognosis in patients with pulmonary embolism treated with unfractionated heparin. A prospective cohort study included 203 patients admitted to a tertiary care center between July 2019 and August 2024 with a confirmed diagnosis of intermediate risk PE treated with UFH. TTR was calculated based on aPTT values during the first 72\u00a0h of hospitalization. The correlation between TTR and mortality rates was assessed. Out of the 203 patients, 116 (57%) achieved therapeutic range at least once, with a mean TTR of 43.1% (\u00b1\u200922.4) and a median of 39%. Nevertheless, the overall mean TTR for all patients was 24.6% (\u00b1\u200927.3), with a median of 18.8%. During the study period 25 (12.3%) patients have died, of them 9 (4.4%) within 30\u00a0days and 16 (7.9%) within one year. Higher TTR was associated with reduced 30-day (p\u2009=\u20090.051) and one-year (p\u2009=\u20090.045) mortality rates. Receiver Operating Characteristic (ROC) analysis identified a TTR threshold of 21.5% for predicting one-year mortality, demonstrating a high negative predictive value (NPV) of 96.8% but a low positive predictive value (PPV) of 12%. Patients with acute PE who achieved higher TTR exhibited better outcomes at 30\u00a0days and one year. However, most patients did not reach adequate TTR levels, leaving its role as an independent prognostic indicator uncertain. Larger studies are necessary to optimize therapeutic strategies and improve outcomes in intermediate-risk PE patients.<\/jats:p>","DOI":"10.1007\/s11239-025-03167-2","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T19:12:17Z","timestamp":1755198737000},"page":"188-195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of time in therapeutic range (TTR) within the first 72\u00a0h on prognosis in patients with pulmonary embolism treated with unfractionated heparin"],"prefix":"10.1007","volume":"59","author":[{"given":"Amit","family":"Ifergan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranel","family":"Loutati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariella","family":"Tvito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mony","family":"Shuvy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shemy","family":"Carasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Deeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louay","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Karmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Manassra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiva","family":"Brin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofir","family":"Rabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Sabouret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amro","family":"Moatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abed","family":"Qadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tali","family":"Bdolah-Abram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Glikson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Asher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"For the Jerusalem Platelets Thrombosis, Intervention in Cardiology (JUPITER-19) Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"issue":"4","key":"3167_CR1","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2020","unstructured":"Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jim\u00e9nez D, Kucher N, Lang IM, Lankeit M, Lorusso R, Mazzolai L, Meneveau N, N\u00ed \u00c1inle F, Prandoni P, Pruszczyk P, Righini M, Torbicki A, Van Belle E, Zamorano JL, ESC Scientific Document Group (2020) 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS). Eur Heart J 41(4):543\u2013603. https:\/\/doi.org\/10.1093\/eurheartj\/ehz405","journal-title":"Eur Heart J"},{"issue":"6","key":"3167_CR2","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/0002-8703(67)90102-0","volume":"74","author":"LA Soloff","year":"1967","unstructured":"Soloff LA, Rodman T (1967) Acute pulmonary embolism. II. clinical. Am Heart J 74(6):829\u2013847. https:\/\/doi.org\/10.1016\/0002-8703(67)90102-0","journal-title":"Am Heart J"},{"issue":"19","key":"3167_CR3","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1056\/NEJM199205073261902","volume":"326","author":"JL Carson","year":"1992","unstructured":"Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI, Schwartz JS, Thompson BT, Popovich J Jr, Hobbins TE (1992) The clinical course of pulmonary embolism. N Engl J Med 326(19):1240\u20131245. https:\/\/doi.org\/10.1056\/NEJM199205073261902","journal-title":"N Engl J Med"},{"issue":"5","key":"3167_CR4","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1177\/1060028018811155","volume":"53","author":"BP St Pierre","year":"2019","unstructured":"St Pierre BP, Edwin SB (2019) Assessment of anticoagulation in patients receiving ultrasound-assisted catheter-directed thrombolysis for treatment of pulmonary embolism. Ann Pharmacother 53(5):453\u2013457. https:\/\/doi.org\/10.1177\/1060028018811155","journal-title":"Ann Pharmacother"},{"issue":"7","key":"3167_CR5","doi-asserted-by":"publisher","first-page":"864","DOI":"10.4065\/82.7.864","volume":"82","author":"AH Kamal","year":"2007","unstructured":"Kamal AH, Tefferi A, Pruthi RK (2007) How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc 82(7):864\u2013873. https:\/\/doi.org\/10.4065\/82.7.864","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"3167_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/acem.13872","volume":"27","author":"CK Prucnal","year":"2020","unstructured":"Prucnal CK, Jansson PS, Deadmon E, Rosovsky RP, Zheng H, Kabrhel C (2020) Analysis of partial thromboplastin times in patients with pulmonary embolism during the first 48 hours of anticoagulation with unfractionated heparin. Acad Emerg Med 27(2):117\u2013127. https:\/\/doi.org\/10.1111\/acem.13872","journal-title":"Acad Emerg Med"},{"issue":"6","key":"3167_CR7","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1001\/archinte.1988.00380060085018","volume":"148","author":"AP Wheeler","year":"1988","unstructured":"Wheeler AP, Jaquiss RD, Newman JH (1988) Physician practices in the treatment of pulmonary embolism and deep venous thrombosis. Arch Intern Med 148(6):1321\u20131325","journal-title":"Arch Intern Med"},{"issue":"2","key":"3167_CR8","doi-asserted-by":"publisher","first-page":"e0148728","DOI":"10.1371\/journal.pone.0148728","volume":"11","author":"AG Bach","year":"2016","unstructured":"Bach AG, Taute BM, Baasai N et al (2016) 30-day mortality in acute pulmonary embolism: prognostic value of clinical scores and anamnestic features. PLoS ONE 11(2):e0148728. https:\/\/doi.org\/10.1371\/journal.pone.0148728","journal-title":"PLoS ONE"},{"issue":"6","key":"3167_CR9","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1378\/chest.09-0959","volume":"137","author":"SB Smith","year":"2010","unstructured":"Smith SB, Geske JB, Maguire JM, Zane NA, Carter RE, Morgenthaler TI (2010) Early anticoagulation is associated with reduced mortality for acute pulmonary embolism. Chest 137(6):1382\u20131390. https:\/\/doi.org\/10.1378\/chest.09-0959","journal-title":"Chest"},{"issue":"9_suppl","key":"3167_CR10","doi-asserted-by":"publisher","first-page":"178S","DOI":"10.1177\/1076029618798944","volume":"24","author":"C Ting","year":"2018","unstructured":"Ting C, Sylvester KW, Schurr JW (2018) Time in the therapeutic range for assessing anticoagulation quality in patients receiving continuous unfractionated heparin. Clin Appl Thromb Hemost 24(9_suppl):178S-181S. https:\/\/doi.org\/10.1177\/1076029618798944","journal-title":"Clin Appl Thromb Hemost"},{"issue":"2","key":"3167_CR11","first-page":"71","volume":"21","author":"NR Campbell","year":"1998","unstructured":"Campbell NR, Hull RD, Brant R, Hogan DB, Pineo GF, Raskob GE (1998) Different effects of heparin in males and females. Clin Invest Med 21(2):71\u201378","journal-title":"Clin Invest Med"},{"issue":"5","key":"3167_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ejvs.2022.08.005","volume":"64","author":"LC Roosendaal","year":"2022","unstructured":"Roosendaal LC, Wiersema AM, Smit JW, Doganer O, Blankensteijn JD, Jongkind V (2022) Editor\u2019s choice\u2014sex differences in response to administration of heparin during non-cardiac arterial procedures. Eur J Vasc Endovasc Surg 64(5):557\u2013565. https:\/\/doi.org\/10.1016\/j.ejvs.2022.08.005","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"4","key":"3167_CR13","doi-asserted-by":"publisher","first-page":"e365","DOI":"10.1055\/s-0040-1719083","volume":"4","author":"AS Streng","year":"2020","unstructured":"Streng AS, Delnoij TSR, Mulder MMG et al (2020) Monitoring of unfractionated heparin in severe COVID-19: an observational study of patients on CRRT and ECMO. TH Open 4(4):e365\u2013e375. https:\/\/doi.org\/10.1055\/s-0040-1719083","journal-title":"TH Open"},{"issue":"Suppl 1","key":"3167_CR14","doi-asserted-by":"publisher","first-page":"S137","DOI":"10.1002\/ajh.23210","volume":"87","author":"J Zehnder","year":"2012","unstructured":"Zehnder J, Price E, Jin J (2012) Controversies in heparin monitoring. Am J Hematol 87(Suppl 1):S137\u2013S140. https:\/\/doi.org\/10.1002\/ajh.23210","journal-title":"Am J Hematol"},{"issue":"2","key":"3167_CR15","first-page":"129","volume":"18","author":"J B\u0115lohl\u00e1vek","year":"2013","unstructured":"B\u0115lohl\u00e1vek J, Dytrych V, Linhart A (2013) Pulmonary embolism, part I: epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism. Exp Clin Cardiol 18(2):129\u2013138","journal-title":"Exp Clin Cardiol"},{"issue":"5","key":"3167_CR16","first-page":"547","volume":"96","author":"JW Eikelboom","year":"2006","unstructured":"Eikelboom JW, Hirsh J (2006) Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost 96(5):547\u2013552","journal-title":"Thromb Haemost"},{"issue":"9","key":"3167_CR17","doi-asserted-by":"publisher","first-page":"720","DOI":"10.7326\/0003-4819-138-9-200305060-00008","volume":"138","author":"R Raschke","year":"2003","unstructured":"Raschke R, Hirsh J, Guidry JR (2003) Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin. Ann Intern Med 138(9):720\u2013723. https:\/\/doi.org\/10.7326\/0003-4819-138-9-200305060-00008","journal-title":"Ann Intern Med"},{"issue":"9","key":"3167_CR18","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMra2104091","volume":"385","author":"JH Levy","year":"2021","unstructured":"Levy JH, Connors JM (2021) Heparin resistance\u2014clinical perspectives and management strategies. N Engl J Med 385(9):826\u2013832. https:\/\/doi.org\/10.1056\/NEJMra2104091","journal-title":"N Engl J Med"},{"issue":"8","key":"3167_CR19","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1111\/jth.15264","volume":"19","author":"P Toulon","year":"2021","unstructured":"Toulon P, Smahi M, De Pooter N (2021) APTT therapeutic range for monitoring unfractionated heparin therapy: significant impact of the anti-Xa reagent used for correlation. J Thromb Haemost 19(8):2002\u20132006. https:\/\/doi.org\/10.1111\/jth.15264","journal-title":"J Thromb Haemost"},{"key":"3167_CR20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.thromres.2021.10.010","volume":"208","author":"R Swayngim","year":"2021","unstructured":"Swayngim R, Preslaski C, Burlew CC, Beyer J (2021) Comparison of clinical outcomes using activated partial thromboplastin time versus antifactor-Xa for monitoring therapeutic unfractionated heparin: a systematic review and meta-analysis. Thromb Res 208:18\u201325. https:\/\/doi.org\/10.1016\/j.thromres.2021.10.010","journal-title":"Thromb Res"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03167-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-025-03167-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03167-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T13:41:43Z","timestamp":1770644503000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-025-03167-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3167"],"URL":"https:\/\/doi.org\/10.1007\/s11239-025-03167-2","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"4 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}